Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2016-11-28 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于诉讼事项的进展公告
Legal Proceedings Report Classification · 100% confidence The document is a detailed announcement regarding the progress of multiple litigation cases involving the company 江苏四环生物股份有限公司. It includes references to civil judgment documents from a local court, specific monetary amounts, legal obligations, and procedural information about appeals. The content is focused on legal proceedings and updates on lawsuits rather than financial performance, management changes, or shareholder information. The document length is 3434 characters, which is relatively short but contains substantive legal information rather than just a notice or summary. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2016-11-28 Chinese
关于诉讼的进展公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from Jiangsu Sihuan Biological Co., Ltd. regarding the progress of several lawsuits involving the company. It details court rulings, property freezes, and the potential impact on company profits. The content focuses on legal proceedings and updates on litigation matters, without financial statements or management discussion. The document length is short (1346 characters), and it is clearly a legal proceedings update rather than a full report or announcement of a report publication. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2016-11-14 Chinese
关于全资子公司签订经营合同的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio Co., Ltd. regarding a contract signed by its wholly-owned subsidiary. It details the contract parties, terms, and potential impact on the company. The document is short (1188 characters) and does not contain financial statements or detailed financial data. It is an announcement about a business contract rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a business contract that does not fit other specific categories.
2016-11-11 Chinese
关于全资子公司经营合同进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the progress of operating contracts of its wholly-owned subsidiary. It discusses strategic cooperation agreements, project details, and delays in project progress. The document is relatively short (1094 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, nor a call transcript or audit report. It is an operational update related to contract progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2016-11-03 Chinese
2016年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 江苏四环生物股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, cash flow, shareholder information, and management statements about the accuracy of the report. The length of the document (7465 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. There is no indication that this is an annual report, earnings release, or other filing types. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2016
2016-10-27 Chinese
2016年第三季度报告全文
Interim / Quarterly Report Classification · 95% confidence The document is titled "江苏四环生物股份有限公司 2016 年第三季度报告全文" which translates to "Jiangsu Sihuan Biological Co., Ltd. 2016 Third Quarter Report Full Text." It contains detailed financial data, including main accounting data, financial indicators, shareholder information, and explanations of changes in financial statement items for the third quarter of 2016. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) indicates this is an Interim / Quarterly Report. The document length is about 15,000 characters, which is consistent with a full report rather than a brief announcement or certification. Therefore, the document should be classified as an Interim / Quarterly Report (IR). 9M 2016
2016-10-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.